CalciMedica Inc. (CALC)
2.00
-0.20 (-9.09%)
At close: Mar 04, 2025, 11:12 AM
No 1D chart data available
| Bid | 1.9 |
| Market Cap | 27.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.45M |
| EPS (ttm) | -1.13 |
| PE Ratio (ttm) | -1.77 |
| Forward PE | -1.64 |
| Analyst | Buy |
| Ask | 2.05 |
| Volume | 292,887 |
| Avg. Volume (20D) | 40,231 |
| Open | 2.07 |
| Previous Close | 2.20 |
| Day's Range | 1.86 - 2.11 |
| 52-Week Range | 1.86 - 6.26 |
| Beta | 1.17 |
About CALC
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC c...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 14, 2023
Employees 13
Stock Exchange NASDAQ
Ticker Symbol CALC
Website https://www.calcimedica.com
Analyst Forecast
According to 3 analyst ratings, the average rating for CALC stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 698.00% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
4 months ago
-22.92%
CalciMedica shares are trading lower after the com...
Unlock content with
Pro Subscription
8 months ago
-32.4%
CalciMedica shares are trading lower. The stock initially gained after the company announced topline data from its Phase 2b CARPO trial of Auxora in acute pancreatitis but has reversed.
